Method for detecting 18 local anesthetics in cosmetics
By combining ultra-high performance liquid chromatography-tandem mass spectrometry with multiple reaction monitoring triggered enhanced ion scanning mode, the problem of misjudgment in the detection of isomers of cocaine-type local anesthetics in cosmetics has been solved, realizing rapid and specific qualitative screening and quantitative analysis, which is applicable to the detection of cosmetics such as creams, lotions, and liquids.
Patent Information
- Application Number
- CN202510379146.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2025-03-28
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2045-03-28
AI Technical Summary
Existing technologies are insufficient to effectively distinguish and detect isomers of cocaine-type local anesthetics with similar structures in cosmetics, leading to misjudgments. Furthermore, statutory testing standards are time-consuming and fail to meet regulatory requirements.
Ultra-high performance liquid chromatography-tandem mass spectrometry (UPLC-QTRAP-MS) combined with multiple reaction monitoring triggered enhanced daughter ion scanning (MRM-IDA-EPI) mode was used to prepare reference solutions and test solutions, and qualitative screening and quantitative analysis were performed using electrospray ionization positive ion mode (ESI+) to obtain secondary mass spectrometry information of target compounds.
It enables rapid, specific, and sensitive detection of 18 local anesthetics in cosmetics, avoiding misjudgments caused by structural similarity, and providing higher sensitivity and analytical efficiency. It is suitable for the detection of cosmetics such as creams, lotions, and liquids.
Smart Images

Figure CN120121749B_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of cosmetic testing, specifically to a method for detecting 18 local anesthetics in cosmetics. Background Technology
[0002] Caine-type local anesthetics are drugs that can locally block the transmission of nerve impulses and are commonly used in the medical field. Adding these substances to cosmetics can provide repair, soothing, anti-wrinkle, and anti-aging effects, but they can also cause adverse reactions such as neurotoxicity or cardiovascular toxicity. Therefore, my country's "Cosmetic Safety Technical Specifications" (2015 edition) lists these ingredients as prohibited components and specifies detection methods for seven local anesthetics, including procainamide. However, some unscrupulous manufacturers evade supervision by adding local anesthetics outside the legally required testing standards, modifying the structure of these drugs, or using byproducts from drug production as raw materials, making them difficult to identify in cosmetic testing. In recent years, our laboratory has detected tetracaine impurities 2, 3, and 6 in cosmetics claiming to have soothing effects for the first time, but no detection methods for these substances have been reported. Given that tetracaine impurity 2 is an isomer of benzocaine impurities 23 and 30, and tetracaine impurity 6 is an isomer of tetracaine impurities 17 and 37, the similar structures of these isomers can easily lead to misidentification during actual detection. The legal standard uses HPLC-DAD combined with QQQ-MS, which is time-consuming and difficult to effectively distinguish these isomers. This invention employs UPLC-QTRAP-MS in MRM-IDA-EPI mode, enabling the acquisition of secondary mass spectrometry information of the target compound simultaneously with conventional qualitative and quantitative mass spectrometry analysis. This allows for more effective differentiation of isomers, with shorter analysis time, higher sensitivity, and the ability to screen a larger number of compounds in a single analysis. Therefore, this invention, based on the seven local anesthetics specified in the legal detection standard, integrates commonly used non-standard local anesthetics and substances such as tetracaine impurity 2, which have not been reported in the literature, to establish a separation and analysis method for 18 cocaine-type local anesthetics, including tetracaine impurity 2, for qualitative screening and content determination. Summary of the Invention
[0003] The technical problem to be solved by this invention is to provide a method that can detect the content of 18 kinds of local anesthetics, and at the same time, the method is simple to operate, specific and sensitive, and avoids misjudgment due to structural similarity.
[0004] The technical solution of the present invention to solve the above-mentioned technical problems is as follows:
[0005] A method for detecting 18 local anesthetics in cosmetics, comprising the following steps:
[0006] (1) Preparation of reference solution: Accurately weigh tetracaine impurity 2, tetracaine impurity 3, tetracaine impurity 6, tetracaine impurity 17, tetracaine impurity 37, benzocaine impurity 30, benzocaine impurity 23, procainamide, lidocaine, procaine, tetracaine, chloroprocaine, bupivacaine, ropivacaine, cincocaine, oxabucine, benzocaine, and prilocaine, dissolve and dilute to prepare reference solution for use;
[0007] (2) Preparation of the test solution;
[0008] (3) Qualitative screening was performed using ultra-high performance liquid chromatography-tandem mass spectrometry: blank solution, test solution and reference solution were injected into the liquid chromatography-mass spectrometry instrument to detect the above 18 local anesthetics.
[0009] Preferred preparation of the reference solution: Accurately weigh 2 mg each of tetracaine impurity 2, tetracaine impurity 3, tetracaine impurity 6, tetracaine impurity 17, tetracaine impurity 37, benzocaine impurity 30, benzocaine impurity 23, procainamide, lidocaine, procaine, tetracaine, chloroprocaine, bupivacaine, ropivacaine, cincocaine, oxabucine, benzocaine, and prilocaine, place them in a 10 mL volumetric flask, dissolve them in methanol and dilute to the mark to prepare a single standard stock solution; then transfer 0.1 mL to the same volumetric flask, and gradually dilute it 10,000 times with negative sample extract to prepare a reference solution with a concentration of 20 ng / mL.
[0010] Preferred preparation of the test solution: Accurately weigh 0.2 g of the test sample, place it in a 15 mL centrifuge tube, add 8 mL of methanol, vortex for 1 min, extract by sonication for 30 min, then add methanol to 10 mL, centrifuge at 13000 r / min for 5 min, and filter the supernatant through a 0.22 μm filter membrane to obtain the test solution;
[0011] Preferably, ultra-high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS / MS) is used for qualitative screening: Chromatographic conditions:
[0012] Chromatographic column: C8 column, 100mm × 2.1mm, 1.7μm / 1.8μm;
[0013] Mobile phase: A - 0.1% ammonia solution, B - 0.1% ammonia solution and acetonitrile;
[0014] Flow rate: 0.2-0.4 mL / min;
[0015] Column temperature: 30-40℃;
[0016] Injection volume: 0.1-5 μL;
[0017] Elution program: 0-1.0 min, 10% B; 1.0-2.5 min, 10-40% B; 2.5-6.0 min, 40% B; 6.0-14.0 min, 40-50% B; 14.0-15.0 min, 50-90% B; 15.0-17.0 min, 90% B; 17.0-17.2 min, 90-10% B; 17.2-18.5 min, 10% B;
[0018] Mass spectrometry conditions:
[0019] Electrospray ionization positive ion mode (ESI) + );
[0020] Ion source spray voltage (IS): +5500V / -4500V;
[0021] Ion source temperature (TEM): 450-550℃;
[0022] Heating gas (GS1): 40-55 psi;
[0023] Auxiliary heating gas (GS2): 40-60 psi;
[0024] Curtain gas (CUR): 15-35 psi;
[0025] Collision air (CAD): Medium;
[0026] Acquisition mode: Multiple reaction monitoring triggered enhanced daughter ion scanning (MRM-IDA-EPI);
[0027] Preferably, ultra-high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS / MS) is used for qualitative screening: blank solution, test solution and reference solution are injected into the liquid chromatography-mass spectrometry instrument, and 18 local anesthetics are detected according to the above chromatographic and mass spectrometric conditions.
[0028] Table 1. Mass Spectrometry Parameters of Compounds
[0029] Serial Number name CAS number Molecular formula <![CDATA[[M+H] + ]]> daughter ions CE / V DP / V 1 Tetracaine impurity 2 4740-24-3 <![CDATA[C 11 H 15 NO2]]> 194.1 94.2、138.0* 26、18 40 2 Tetracaine impurity 3 71839-12-8 <![CDATA[C 12 H 17 NO2]]> 208.1 120.0、152.0* 25、19 40 3 Tetracaine impurity 6 94-32-6 <![CDATA[C 13 H 19 NO2]]> 222.1 138.1、166.1* 23、19 50 4 Tetracaine impurity 17 1056627-94-1 <![CDATA[C 13 H 19 NO2]]> 222.1 138.1、166.1* 28、16 30 5 Tetracaine impurity 37 512175-79-0 <![CDATA[C 13 H 19 NO2]]> 222.1 138.1、166.1* 24、17 40 6 Benzocaine impurity 23 94-25-7 <![CDATA[C 11 H 15 NO2]]> 194.1 120.0、138.0* 28、13 5 7 Benzocaine impurity 30 10287-53-3 <![CDATA[C 11 H 15 NO2]]> 194.1 151.1*、166.1 32、22 60 8 Procainamide Hydrochloride 614-39-1 <![CDATA[C 13 H 22 ClN3O]]> 236.1 120.0、163.1* 39、21 40 9 Lidocaine 137-58-6 <![CDATA[C 14 H 22 N2O]]> 235.1 58.0、86.0* 52、21 40 10 Procaine hydrochloride 51-05-8 <![CDATA[C 13 H 21 ClN2O2]]> 237.1 100.0*、120.0 20、32 40 11 Tetracaine 94-24-6 <![CDATA[C 15 H 24 N2O2]]> 265.2 72.0、176.1* 20、20 40 12 Chloroprocaine hydrochloride 3858-89-7 <![CDATA[C 13 H 20 Cl2N2O2]]> 271.1 100.0*、154.0 21、32 40 13 bupivacaine hydrochloride 73360-54-0 <![CDATA[C 18 H 31 ClN2O2]]> 289.2 84.0、140.1* 55、27 60 14 Ropivacaine Mesylate 854056-07-8 <![CDATA[C 18 H 30 N2O4S]]> 275.1 84.1、126.1* 56、26 60 15 Cyncocaine hydrochloride 61-12-1 <![CDATA[C 20 H 30 ClN3O2]]> 344.2 215.1、271.2* 40、28 80 16 Obucaine hydrochloride 5987-82-6 <![CDATA[C 17 H 29 ClN2O3]]> 309.2 100.1、192.1* 23、24 60 17 Benzocaine 94-09-7 <![CDATA[C9H 11 NO2]]> 166.0 120.0、138.0* 25、14 30 18 Primacaine 721-50-6 <![CDATA[C 13 H 20 N2O]]> 221.1 86.1*、136.0 17、25 30
[0030] Note: *Quantitative ion pairs
[0031] Preferably, the test sample in step (2) is a cream, lotion, or water-based cosmetic.
[0032] Preferably, the chromatographic column in step (3) is a C8 column, 100mm×2.1mm, 1.7μm.
[0033] Preferably, the column temperature in step (3) is 35°C.
[0034] Preferably, the flow rate in step (3) is 0.3 mL / min.
[0035] Preferably, the ionization voltage in step (3) is 5500V.
[0036] Preferably, the ion source temperature in step (3) is 500°C;
[0037] Preferably, the heating gas in step (3) is 55 psi;
[0038] Preferably, the auxiliary heating gas in step (3) is 55 psi;
[0039] Preferably, the curtain gas in step (3) is 25 psi;
[0040] Preferably, the injection volume in step (3) is 1 μL.
[0041] In this invention, if there is a conflict between the Chinese name and the structural formula of a compound, the structural formula shall prevail.
[0042] The principle of this method is as follows: the test sample is extracted with methanol, separated by a C8 column, eluted with 0.1% ammonia solution and 0.1% ammonia-acetonitrile solution, and eluted using an electrospray ionization source in positive ion mode (ESI). + Ionization was performed, and multiple reaction monitoring triggered enhanced ion scanning (MRM-IDA-EPI) mode was used for detection. Based on the chromatographic retention time and relative ion abundance ratio, the samples were initially identified as suspected positive samples. Further comparison of the secondary mass spectra of the suspected positive samples and the control was used for confirmation, and external standard method was used for quantification.
[0043] Result judgment:
[0044] If a qualitative / quantitative ion-pair chromatographic peak with the same retention time as the 18 local anesthetic reference standards appears in the test sample, and the relative ion abundance ratio (k) does not exceed the maximum permissible deviation (k>50%, maximum permissible deviation is ±20%; 50%≥k>20%, maximum permissible deviation is ±25%; 20%≥k>10%, maximum permissible deviation is ±30%; k≤10%, maximum permissible deviation is ±50%), it is judged as a suspected positive sample. By further comparing the secondary mass spectra of the suspected positive sample and the reference standards, if the two are consistent, it is determined that the local anesthetic component in this experiment has been added, and the component is quantified by the external standard method.
[0045] If an ion-pair chromatographic peak with the same retention time as the 18 local anesthetic reference standards appears in the test sample, and if the relative ion abundance ratio (k) exceeds the maximum permissible deviation and is inconsistent with the secondary mass spectrum of the reference standards, then it is determined that these 18 local anesthetics have not been added to the sample, and their detection concentration is calculated.
[0046] If no chromatographic peak of ion pair with the retention time of the 18 local anesthetic reference standards appears in the test sample, it is determined that these 18 local anesthetics have not been added to the sample, and their detection concentration is calculated.
[0047] The beneficial effects of this invention are as follows:
[0048] 1. The method of the present invention can specifically, sensitively and rapidly perform qualitative screening and quantitative analysis of 18 local anesthetics, such as tetracaine impurity 2, in cosmetics, avoiding misjudgment caused by similar compound structures.
[0049] 2. The method of the present invention is mainly applicable to the testing of 18 kinds of local anesthetics, such as tetracaine impurity 2, in ointments, emulsions, and aqueous solutions.
[0050] 3. Among the 18 local anesthetics tested in this experiment, including tetracaine impurity 2, tetracaine impurity 3, tetracaine impurity 6, tetracaine impurity 17, tetracaine impurity 37, benzocaine impurity 23, and benzocaine impurity 30, there are currently no detection methods. This method can accurately screen and confirm them, providing strong technical support for supervision. Attached Figure Description
[0051] Figure 1 Extraction ion chromatograms (EIC chromatograms) of 18 local anesthetics including Tetracaine Impurity 2 (1: Tetracaine Impurity 2, 2: Procainamine, 3: Benzocaine, 4: Procaine, 5: Chloroprocaine, 6: Primacaine, 7: Benzocaine Impurity 23, 8: Lidocaine, 9: Benzocaine Impurity 30, 10: Tetracaine, 11: Ropivacaine, 12: Tetracaine Impurity 3, 13: Obubucaine, 14: Tetracaine Impurity 17, 15: Bupivacaine, 16: Tetracaine Impurity 37, 17: Tetracaine Impurity 6, 18: Cincocaine);
[0052] Figure 2 Secondary mass spectrum of tetracaine impurity 2 reference solution;
[0053] Figure 3 Secondary mass spectrum of prilocaine reference solution;
[0054] Figure 4 Secondary mass spectrum of lidocaine reference solution;
[0055] Figure 5 Secondary mass spectrum of tetracaine reference solution;
[0056] Figure 6 Secondary mass spectrum of tetracaine impurity 3 reference solution;
[0057] Figure 7 Secondary mass spectrum of tetracaine impurity 6 reference solution;
[0058] Figure 8 EIC chromatogram of the test solution in Example 2 (1: Tetracaine impurity 2, 2: Primacaine, 3: Lidocaine, 4: Tetracaine);
[0059] Figure 9 EIC chromatogram of the test solution in Example 2 (5: Tetracaine impurity 3, 6: Tetracaine impurity 6);
[0060] Figure 10 EIC chromatogram of the test solution in Example 3 (1: Tetracaine impurity 2, 2: Primacaine, 3: Lidocaine, 4: Tetracaine);
[0061] Figure 11 EIC chromatogram of the test solution in Example 3 (5: Tetracaine impurity 3, 6: Tetracaine impurity 6);
[0062] Figure 12 EIC chromatogram of the test solution in Example 4 (1: Tetracaine impurity 2, 2: Primacaine, 3: Lidocaine, 4: Tetracaine);
[0063] Figure 13 EIC chromatogram of the test solution in Example 4 (5: Tetracaine impurity 3). Detailed Implementation
[0064] The present invention is illustrated below with reference to examples, but is not intended to limit the invention. Any simple substitutions or modifications made to the present invention by those skilled in the art are within the scope of the technical solutions protected by this invention.
[0065] Example 1:
[0066] Screening of chromatography, mass spectrometry and sample processing conditions
[0067] 1. Reagents and Materials
[0068] Ultrapure water; methanol and acetonitrile were used for mass spectrometry; ammonia was of analytical grade; Tetracaine impurity 2, Tetracaine impurity 3, Tetracaine impurity 6, Benzocaine impurity 23, and Benzocaine impurity 30 reference standards (source: STD PHARM); Tetracaine impurity 17 and Tetracaine impurity 37 (source: CATO); Procainamide hydrochloride, Procaine hydrochloride, Chloroprocaine hydrochloride, Benzocaine, Lidocaine, Tetracaine, Cincocaine hydrochloride, and Primacaine reference standards (source: BePure); Bupivacaine hydrochloride, Ropivacaine mesylate, and Obubucaine hydrochloride reference standards (source: National Institutes for Food and Drug Control).
[0069] 2. Instruments
[0070] Sciex Q-trap 6500+ triple quadrupole-linear ion trap composite mass spectrometer (Shanghai Aibocaisi Analytical Instruments Trading Co., Ltd.), KQ-300DA CNC ultrasonic cleaner (Kunshan Ultrasonic Instruments Co., Ltd.), Metler-Toledo XP56 electronic balance (accuracy 0.001mg, Metler-Toledo Instruments (Shanghai) Co., Ltd.), Milli-Q pure water system (Millipore).
[0071] 3. Chromatographic conditions
[0072] Chromatographic column: C8 column, ACQUITY UPLC BEH C8, 1.7μm, 2.1×100mm;
[0073] Mobile phase: A - 0.1% ammonia solution, B - 0.1% ammonia solution and acetonitrile;
[0074] Flow rate: 0.3 mL / min;
[0075] Column temperature: 35℃;
[0076] Injection volume: 1 μL;
[0077] Elution program: 0-1.0 min, 10% B; 1.0-2.5 min, 10-40% B; 2.5-6.0 min, 40% B; 6.0-14.0 min, 40-50% B; 14.0-15.0 min, 50-90% B; 15.0-17.0 min, 90% B; 17.0-17.2 min, 90-10% B; 17.2-18.5 min, 10% B;
[0078] 4. Mass spectrometry conditions
[0079] Electrospray ionization positive ion mode (ESI) + );
[0080] Ion source spray voltage (IS): 5500V;
[0081] Ion source temperature (TEM): 500℃;
[0082] Heating gas (GS1): 55 psi;
[0083] Auxiliary heating gas (GS2): 55 psi;
[0084] Curtain gas (CUR): 25 psi;
[0085] Collision air (CAD): Medium;
[0086] Acquisition mode: Multiple reaction monitoring triggered enhanced daughter ion scanning (MRM-IDA-EPI).
[0087] 5. Preparation of the analyte
[0088] (1) Preparation of reference solutions: Accurately weigh 2 mg each of tetracaine impurity 2, tetracaine impurity 3, tetracaine impurity 6, tetracaine impurity 17, tetracaine impurity 37, benzocaine impurity 30, benzocaine impurity 23, procainamide, lidocaine, procaine, tetracaine, chloroprocaine, bupivacaine, ropivacaine, cincocaine, oxabucine, benzocaine, and prilocaine, and place them in 10 mL volumetric flasks respectively. Dissolve them in methanol and dilute to the mark to prepare single standard stock solutions. Then transfer 0.1 mL to the same volumetric flask and gradually dilute it 10,000 times with negative sample extract to prepare reference solutions with a concentration of 20 ng / mL.
[0089] (2) Sample preparation: Accurately weigh 0.2g of the test sample, place it in a 15mL centrifuge tube, add 8mL of methanol, vortex for 1min, extract by sonication for 30min, add methanol to 10mL, centrifuge at 13000r / min for 5min, take the supernatant and filter it through a 0.22μm filter membrane to obtain the test sample solution.
[0090] (3) Qualitative screening was performed using ultra-high performance liquid chromatography-tandem mass spectrometry: blank solution, test solution and reference solution were injected into the liquid chromatography-mass spectrometry instrument for detection.
[0091] Table 2. Selection of Mobile Phase
[0092]
[0093] Table 3. Selection of ammonia concentration in the mobile phase
[0094] Method number Ammonia concentration (%) result 1 0.02 Sincocaine has severe tailing. 2 0.05 The peak shapes of each compound showed slight tailing, and the compounds responded well. 3 0.10 Each compound showed good peak shape and good compound response. 4 0.15 The peak shapes of each compound were good, while the response of the other compound was slightly lower.
[0095] Table 4. Selection of Stationary Phase
[0096]
[0097] Table 5. Column Temperature Selection
[0098] Method number Column temperature result 1 30℃ The compounds were well separated, but the system pressure was too high. 2 35℃ The compounds were well separated. 3 40℃ Poor separation of compounds
[0099] Table 6. Selection of Extraction Solvent
[0100]
[0101] Methodological investigation
[0102] Linear range:
[0103] Appropriate amounts of the stock solution of 18 components, including tetracaine impurity 2, were transferred and serially diluted with negative sample extract to prepare a series of control solutions with final concentrations of 1, 2, 5, 10, 20, and 50 ng / mL. Linear fitting was performed on peak area (Y) against mass concentration (X), and the linear equation and correlation coefficient were calculated (see Table 7). The results showed that all compounds exhibited good linearity (r>0.999) within the range of 1-50 ng / mL.
[0104] Table 7.18: Linear range, linear equation, and correlation coefficient of 18 local anesthetics
[0105]
[0106]
[0107] Limit of detection and limit of quantitation:
[0108] Take an appropriate amount of the stock solution of 18 components, including tetracaine impurity 2, and use the extract of ointment-type negative samples as solvent. The limits of detection and limits of quantitation are the concentrations of each standard solution at signal-to-noise ratios of 3 and 10, respectively. The results are shown in Table 8.
[0109] Table 8. Limits of detection and limits of quantitation for 18 local anesthetics
[0110]
[0111]
[0112] Recovery rate and precision:
[0113] The recovery rate of the spiked sample was determined using aqueous and ointment samples with negative test results as the matrix. 0.2 g of the negative sample was weighed into a 15 mL graduated centrifuge tube, and 40 μL of a mixed standard solution of 18 local anesthetics with a mass concentration of 500 ng / mL was added. Six parallel samples were prepared according to step (2), injected, and analyzed. A blank matrix extract spiked solution was prepared concurrently and analyzed. The ratio of the spectral response of the analyte in the sample solution to that of the standard solution at the same concentration was calculated to evaluate the recovery rate and precision of the method (Table 9).
[0114] Table 9. Recovery rates and precision of 18 local anesthetics (n=6)
[0115]
[0116] Matrix effect:
[0117] Standard curves were prepared using extracts of aqueous solutions and ointments as blank matrices, respectively. The matrix effect (ME) was calculated as the ratio of the slope of the matrix standard curve to that of the solvent standard curve, and the results are shown in Table 10. The results showed that the matrix effect of the 18 compounds ranged from 0.44 to 1.16, indicating that different matrix types have a certain degree of influence on the determination of the target compounds. Therefore, this method uses a accompanying blank matrix standard curve.
[0118] Table 10. Matrix effects of 18 local anesthetics
[0119]
[0120] stability
[0121] A mixed reference solution with a concentration of 10 ng / mL was placed in an autosampler and injected at 1 h, 6 h, 24 h, 48 h, and 72 h after preparation. The mass spectrometry response of each component was calculated, and the results showed good stability.
[0122] Example 2:
[0123] Accurately weigh 0.2g of a certain batch of soothing emulsion, place it in a 15mL centrifuge tube, add 8mL of methanol, vortex for 1min, sonicate for 30min, add methanol to 10mL, centrifuge at 13000r / min for 5min, take the supernatant and filter it through a 0.22μm filter membrane, inject it into a liquid chromatography-mass spectrometry (LC-MS) instrument for analysis.
[0124] Results analysis:
[0125] The results showed that the sample solution exhibited chromatographic peaks at retention times of 3.11, 6.58, 9.39, 10.60, 11.98, and 14.86 min, which were consistent with the retention times of the reference standards for tetracaine impurity 2, prilocaine, lidocaine, tetracaine, tetracaine impurity 3, and tetracaine impurity 6, respectively (see Appendix). Figure 1 The relative ion abundance ratio (k) of the two ions (8, 9) did not exceed the maximum permissible deviation, and the corresponding secondary mass spectra... Figure 1 The contents of tetracaine impurity 2, prilocaine, lidocaine, tetracaine, tetracaine impurity 3, and tetracaine impurity 6 were measured to be 2775, 9206, 9621, 13757, 40, and 100 mg / kg, respectively.
[0126] Example 3:
[0127] Accurately weigh 0.2g of a certain batch of soothing emulsion, place it in a 15mL centrifuge tube, add 8mL of methanol, vortex for 1min, sonicate for 30min, add methanol to 10mL, centrifuge at 13000r / min for 5min, take the supernatant and filter it through a 0.22μm filter membrane, inject it into a liquid chromatography-mass spectrometry (LC-MS) instrument for analysis.
[0128] Results analysis:
[0129] The results showed that the sample solution exhibited chromatographic peaks at retention times of 3.11, 6.59, 9.41, 10.61, 11.98, and 14.86 min, which were consistent with the retention times of the reference standards for tetracaine impurity 2, prilocaine, lidocaine, tetracaine, tetracaine impurity 3, and tetracaine impurity 6, respectively (see Appendix). Figure 1 The relative ion abundance ratio (k) of the two ions (10, 11) did not exceed the maximum permissible deviation, and the corresponding secondary mass spectra... Figure 1 The contents of tetracaine impurity 2, prilocaine, lidocaine, tetracaine, tetracaine impurity 3, and tetracaine impurity 6 were measured to be 3849, 10315, 8229, 11221, 38, and 98 mg / kg, respectively.
[0130] Example 4:
[0131] Accurately weigh 0.2g of a certain batch of soothing cream, place it in a 15mL centrifuge tube, add 8mL of methanol, vortex for 1min, sonicate for 30min, add methanol to 10mL, centrifuge at 13000r / min for 5min, take the supernatant and filter it through a 0.22μm filter membrane, and inject it into a liquid chromatography-mass spectrometry (LC-MS) instrument for detection.
[0132] Results analysis:
[0133] The results showed that the sample solution exhibited chromatographic peaks at retention times of 3.13, 6.58, 9.40, 10.60, and 12.00 min, which were consistent with the retention times of the reference standards for tetracaine impurity 2, prilocaine, lidocaine, tetracaine, and tetracaine impurity 3, respectively (see Appendix). Figure 1 (12, 13) The relative ion abundance ratio (k) did not exceed the maximum permissible deviation, and the corresponding secondary mass spectra... Figure 1 The contents of tetracaine impurity 2, prilocaine, lidocaine, tetracaine, and tetracaine impurity 3 were measured to be 3140, 1171, 44244, 39945, and 145 mg / kg, respectively.
[0134] The above description is only a preferred embodiment of the present invention. It should be noted that those skilled in the art can make several modifications and improvements without departing from the inventive concept of the present invention, and these all fall within the protection scope of the present invention.
Claims
1. A method for detecting 18 local anesthetics in cosmetics, characterized in that, Includes the following steps: (1) Preparation of reference solution: Accurately weigh tetracaine impurity 2, tetracaine impurity 3, tetracaine impurity 6, tetracaine impurity 17, tetracaine impurity 37, benzocaine impurity 30, benzocaine impurity 23, procainamine, lidocaine, procaine, tetracaine, chloroprocaine, bupivacaine, ropivacaine, cincocaine, oxabucine, benzocaine, and prilocaine, dissolve and dilute to prepare reference solution; (2) Preparation of the test solution; (3) Qualitative screening was performed using ultra-high performance liquid chromatography-tandem mass spectrometry: blank solution, test solution, and reference solution were injected into the liquid chromatography-mass spectrometry instrument to detect the above 18 local anesthetics; the specific conditions for qualitative screening using ultra-high performance liquid chromatography-tandem mass spectrometry in step (3) are as follows: Chromatographic conditions: Column: C8 / C 18 Chromatographic column, 100 mm × 2.1 mm, 1.7 μm / 1.8 μm; Mobile phase: A - 0.1% ammonia solution, B - 0.1% ammonia solution and acetonitrile; Flow rate: 0.2-0.4 mL / min; Column temperature: 30-40 ℃; Injection volume: 0.1-5 μL; Elution program: 0-1.0 min, 10% B; 1.0-2.5 min, 10-40% B; 2.5-6.0 min, 40% B; 6.0-14.0min, 40-50% B; 14.0-15.0 min, 50-90% B; 15.0-17.0 min, 90% B; 17.0-17.2 min, 90-10% B; 17.2-18.5min, 10% B; Mass spectrometry conditions: Electrospray ionization positive ion mode; Ion source spray voltage: +5500V / -4500V; Ion source temperature: 450-550℃; Heating gas: 40-55 psi; Auxiliary heating gas: 40-60 psi; Air curtain gas: 15-35 psi; Collision gas: Medium; Acquisition mode: Multiple reaction monitoring triggered enhanced proton scan.
2. The method according to claim 1, characterized in that, The specific steps (1) are as follows: accurately weigh 2 mg of each of the above 18 local anesthetic reference standards, place them in a 10 mL volumetric flask, dissolve them in methanol and dilute to the mark to prepare a single standard stock solution; then transfer 0.1 mL to the same volumetric flask, gradually dilute it 10,000 times with negative sample extract to prepare a reference standard working solution with a concentration of 20 ng / mL.
3. The method according to claim 1, characterized in that, The specific steps (2) are as follows: accurately weigh 0.2g of the test sample, place it in a 15 mL centrifuge tube, add 8 mL of methanol, vortex for 1 min, extract by ultrasonication for 30 min, add methanol to 10 mL, centrifuge at 13000 r / min for 5 min, take the supernatant and filter it through a 0.22 μm filter membrane to obtain the test sample solution.
4. The method according to claim 1, characterized in that, The test samples in step (2) are ointments, creams, lotions, and water-based cosmetics.
5. The method according to claim 1, characterized in that, In step (3), the chromatographic column is an ACQUITY UPLCBEH C8 column, 1.7 μm, 2.1 × 100 mm.
6. The method according to claim 1, characterized in that, In step (3), the column temperature is 35 ℃ and the flow rate is 0.3 mL / min.
7. The method according to claim 1, characterized in that, In step (3), the ionization voltage is 5500V and the ion source temperature is 500℃.
8. The method according to claim 1, characterized in that, In step (3), the heating gas is 55 psi and the auxiliary heating gas is 55 psi.
9. The method according to claim 1, characterized in that, In step (3), the curtain gas is 25 psi and the injection volume is 1 μL.
Citation Information
Patent Citations
Method for detecting content of anesthetic compounds in cosmetics
CN118731256A
Long-lasting anaesthetic formulation
WO2023242417A1
